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Structured abstract 32 
Introduction: The Tasmanian devil (Sarcophilus harrisii) is the largest extant carnivorous 33 
marsupial. Since 1996, its population has declined by 77% primarily due to a clonal 34 
transmissible tumor, known as devil facial tumor (DFT1) disease. In 2014, a second 35 
transmissible devil facial tumor (DFT2) was discovered. DFT1 and DFT2 are nearly 100% 36 
fatal. 37 
Areas covered: We review DFT control approaches and propose a rabies-style oral bait vaccine 38 
(OBV) platform for DFTs. This approach has an extensive safety record and was a primary 39 
tool in large-scale rabies virus elimination from wild carnivores across diverse landscapes. Like 40 
rabies virus, DFTs are transmitted by oral contact, so immunizing the oral cavity and 41 
stimulating resident memory cells could be advantageous. Additionally, exposing infected 42 
devils that already have tumors to OBVs could serve as an oncolytic virus immunotherapy. 43 
The primary challenges may be identifying appropriate DFT-specific antigens and optimization 44 
of field delivery methods. 45 
Expert commentary: DFT2 is currently found on a peninsula in southern Tasmania, so an OBV 46 
that could eliminate DFT2 should be the priority for this vaccine approach. Translation of an 47 
OBV approach to control DFTs will be challenging, but the approach is feasible for combatting 48 
ongoing and future disease threats.  49 
 50 
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1. Introduction 55 
1.1. The Tasmanian devil and transmissible cancers 56 
The Tasmanian devil (Sarcophilus harrisii) is the largest extant carnivorous marsupial. The 57 
species became extinct on mainland Australia around 3,000 years ago and is presently found 58 
only on the island State of Tasmania [1,2] (Fig. 1). Since 1996 the devil population has declined 59 
by 77% and is now listed as endangered [3,4]. The precipitous population decline is largely 60 
due to the emergence of a clonal, transmissible cancer called devil facial tumor (DFT1) that is 61 
usually fatal [5–7]. 62 
 63 
In 2014, a second transmissible devil facial tumor (DFT2) that originated independently of 64 
DFT1 was discovered in wild devils [8]. A few cases of natural DFT1 regression have been 65 
reported [9–11], but no regressions or survival have been reported to date for DFT2 [8,12]. 66 
Like DFT1, DFT2 likely originated from a Schwann cell [13,14]. There are only nine known 67 
naturally-transmissible cancers, two of which occur in devils [5,8,15–17]. Independent studies 68 
from the San Diego Zoo (1979) and the Tasmanian Department of Primary Industries, Parks, 69 
Water and Environment (2019) performed 40 years apart and using different founder stocks 70 
reported that 50% and 43% of devils in captivity developed neoplasms [18,19]. A 1990 study 71 
from the Taronga Zoo (Sydney, Australia) also stated that "dasyurids, especially Tasmanian 72 
devils, are particularly prone to develop proliferative lesions" [20]. Large studies on neoplasms 73 
in captive wildlife by the San Diego Zoo (n=10,317) [19,21] and Taipei Zoo (n=2,657) [22], 74 
and domestic animals by the USA National Cancer Institute (n=202,277) reported cancer 75 
incidence generally less than 10% for zoo animals and domestic animals [23]. In addition to 76 
DFTs, habitat changes, road fatalities, dog attacks, and inbreeding, further limit the chance of 77 
population recovery [4,24]. The predisposition for cancer coupled with anthropogenic 78 
pressures present a clear threat to the long-term persistence of Tasmanian devils in the wild.  79 
 80 
A regionally distributed vaccine could be used to prevent DFT2 from spreading across the state 81 
(Fig. 1) and provide an adaptable platform for ongoing (i.e. DFT1) and future disease threats. 82 
This Special Report will provide an overview of DFT vaccine options and their benefits and 83 
limitations. The vaccine option that balances safety with the greatest likelihood of success is 84 
an oncolytic viral vector that expresses DFT-specific antigens and is packaged inside an oral 85 
bait vaccine (OBV) capsule attractive to Tasmanian devils (Fig. 2). Our aim is to develop an 86 
adaptable OBV platform that builds on nearly five decades of research and field application of 87 
the highly successful OBV approach that has been used to control rabies in more than 30 88 
countries [25,26]. 89 
 90 
2. Current and future devil monitoring and management 91 
Early statistical modelling (2007) predicted that DFT1 would spread across the entire range of 92 
the devil within 5-10 years, with extinction “a real possibility and an unacceptable risk” [7]. 93 
DFT1 has not yet reached the northwest and southwest regions of Tasmanian, so these regions 94 
remain DFT-free for the time being. DFT-affected devil subpopulations generally persist at 10-95 
20% of historical levels and no local extinctions have been reported [4]. With DFT1, juvenile 96 
devils (< 1 year of age) are generally not affected, vertical transmission has not been reported, 97 
and primary transmission is hypothesized to occur during mating [27,28]. Precocial breeding 98 
of one-year old females and more pouch young per female has maintained small local 99 
populations [4,29]. However, as the devil pouch can accommodate a maximum of four joeys 100 
and further reduction of the breeding age to less than one-year of age is not expected, it is 101 
unlikely that increased precocial breeding can increase population density or compensate for 102 
additional environmental pressures on the wild population. 103 
 104 
Genetic analysis demonstrating strong linkage disequilibrium pre- and post-DFT1 arrival have 105 
been used to infer positive selection in genomic regions near particular variants and suggest 106 
that the population is rapidly evolving in response to DFT1. However, disease prevalence 107 
remains > 20% and devils > 3 years old represent less than 10% of the population following 108 
the arrival of DFT1 (4,26). Additionally, the study that documents rapid evolution also states 109 
that Tasmanian devils have "extremely low levels of genetic diversity"; it is unknown how a 110 
species with minimal genetic diversity and is prone to cancer can simultaneously respond to 111 
evolutionary pressures from two different transmissible tumors. 112 
 113 
One early disease management strategy considered was culling of infected animals, but trials 114 
concluded that removing infected devils did not impact the local prevalence of DFT1 [30]. 115 
Therefore, managers have focused on devil breeding programs to establish disease-free 116 
insurance populations in captive facilities. A DFT-free devil population was also established 117 
on Maria Island off the east coast of Tasmania in 2012 [31], which is the primary source of 118 
devils translocated to mainland Tasmania to boost population numbers and genetic diversity in 119 
diseased areas. The Maria Island population, together with the captive-breeding program, 120 
accounts for an extensive insurance population (~700 devils). 121 
 122 
Another potential management strategy is to identify DFT-resistant devils and "attempt to 123 
spread the resistant alleles into affected populations" [32]. However, the mechanism for 124 
resistance and whether the "resistance" phenotype would have similar effects in other outbred 125 
populations is unknown. Additionally, translocation among wild populations risks introducing 126 
DFT strains with higher virulence[33] due to the long latent period of DFT, which can extend 127 
for at least 13 months in some cases (Save the Tasmanian Devil Program, personal 128 
communication). For example, DFT strain replacement has been documented to result in a 129 
"rapid increase in disease prevalence, population decline and reduced mean age of the 130 
population" [34]. Other management options for reducing or controlling the impact of DFT1 131 
and DFT2 have been considered but are generally limited to specific regions. Our proposal is 132 
to develop a vaccine that can suppress or eliminate DFT1 and DFT2 infections to allow wild 133 
devil populations to recover. 134 
 135 
3. DFT vaccine and immunotherapy approaches 136 
3.1. Whole-cell killed vaccine 137 
A whole-DFT cell vaccine approach was a logical starting point because the DFT cells have 138 
the potential to express the full suite of tumor antigens [35–37]. However, the clonal DFT cells 139 
have been transmitted through many devils and evolution has refined their immune-evading 140 
ability, resulting in a non-immunogenic cell (e.g. low MHC-I expression) that can express 141 
immunosuppressive checkpoint molecules and cytokines [38–40]. Furthermore, whole cells 142 
can also express the full suite of "self" antigens associated with healthy cells. Regulatory T 143 
cells and other tolerogenic cells that recognize the normal "self" proteins can create an 144 
immunosuppressive environment that impedes anti-tumor immunity in humans and mice [41]. 145 
 146 
3.2. Live-attenuated vaccine 147 
Live vaccines closely mimic the natural course of infection and are generally the most effective 148 
at stimulating lifetime immunity. Live DFT cells could be modified (“attenuated”) to reduce 149 
the likelihood of seeding new tumors. For example, we have developed DFT cells that can be 150 
induced to express IFNγ and upregulate MHC-I [42]. Coupling upregulation of 151 
immunostimulatory genes with mechanisms that control DFT cell proliferation (e.g. "suicide 152 
genes") and inhibitory pathways (e.g. PDL1 blocking antibodies, PDL1 gene knockout) could 153 
induce a strong anti-tumor response while enhancing the safety profile. Additional attenuation 154 
mechanisms, such as tissue-culture adapted strains and site-directed evolution of the pathogen, 155 
can reduce the probability of reversion to virulence [43–45]. However, this live-DFT cell 156 
approach would be difficult to implement in a field setting. 157 
 158 
3.3. Viral vector-based vaccines 159 
Oncolytic viruses that preferentially infect tumor cells have shown promise in human clinical 160 
trials [46,47]. These immunogenic viruses can directly lyse tumor cells, releasing damage-161 
associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs), 162 
which stimulate antigen presenting cell (APC) and effector cell migration to the tumor 163 
microenvironment (Fig. 3). Oncolytic viral vectors that are modified to express genes coding 164 
for "cargo" (e.g. tumor-specific antigens, cytokines) have prophylactic and immunotherapeutic 165 
potential. The viral vectors are usually attenuated to limit replication in the target host and 166 
minimize risk of transmission to secondary hosts. 167 
 168 
3.4. Recombinant protein-based vaccine 169 
The safest approach to a DFT vaccine combines immunostimulatory adjuvants and purified 170 
recombinant proteins. Effective adjuvants that provide immunogenic "danger signals" have 171 
already been identified [48,49] and could be used with recombinant protein targets. Non-172 
synonymous DNA mutations that create altered protein sequences in DFTs can yield 173 
neoantigens likely to be viewed as foreign proteins by the host immune system. Clonal DFT 174 
cells have accumulated thousands of DNA mutations over years of continued transmission. 175 
Interestingly, the majority of these mutations are in non-coding regions or are synonymous 176 
mutations (i.e. protein sequence and function not altered) [50]. Of the 2,884 single nucleotide 177 
variants (SNVs) and 410 insertions/deletions identified in two DFT1 cell lines but not in 46 178 
host devils, only 18 of these variations resulted in non-synonymous mutations. DFT2 has 3,591 179 
SNVs and 572 insertions/deletions, but only 19 non-synonymous mutations. Short peptides 180 
that contain the non-synonymous portion of the protein could be used as alternative targets to 181 
full-length recombinant proteins [51]. A recent discovery that aberrantly expressed proteins 182 
from non-coding regions can function as tumor-specific antigens [52] is another possibility 183 
worth exploring. 184 
 185 
4. An oral bait vaccine (OBV) for DFT1 and DFT2 is needed 186 
Recent modelling (2019) has predicted a 20% chance of devil extinction due to DFT1 in the 187 
next 100 years and that "management interventions are unlikely to be necessary to ensure 188 
persistence of Tasmanian devil populations" [53]. However, these predictions are based on data 189 
from only a single subpopulation representing only a fraction of the data from long-term studies 190 
that have collected samples from "over 10,000 individuals and 2,000 tumor biopsies" [54]. 191 
Another study that used statewide data predicted long-term coexistence of devils and DFT1, 192 
but the devil population would be limited  to 9% of pre-DFT1 size that could lead to "dramatic 193 
effects on the Tasmanian ecosystem" [55]. Furthermore, the predictions did not consider 194 
dynamic impacts of other ecological factors, such as inbreeding, social behavior, and the Allee 195 
effect (i.e. reduced fitness in small populations) [24,56–61]. Additionally, further negative 196 
consequences of DFT2, which has been co-circulating since 2014 [8], were not acknowledged 197 
in the manuscripts [53]. The ongoing spread of DFT1 and lack of population recovery from 198 
this infection, the relatively new threat of DFT2 and anthropogenic threats lead to continuing 199 
uncertainty for the long-term persistence of wild devils. Here we present a challenging but 200 
feasible OBV option to eliminate DFT2, combat the ongoing DFT1 threat, and provide a 201 
platform for managing future disease threats. 202 
 203 
The ideal vaccine must be potent, innocuous to humans and other animals, and exhibit 204 
negligible excretion and low horizontal transmission risk in hosts. It must also be thermostable 205 
for several days at ambient temperatures, genetically stable concerning reversion to a virulent 206 
phenotype, free of contaminants, and relatively inexpensive to produce [62,63]. Several factors 207 
support the reality of a vaccine to block transmission and eliminate DFTs. First, vaccination of 208 
translocated devils from insurance populations has demonstrated that strong anti-tumor 209 
immune responses can be induced in vaccinated devils [48]. Second, a DFT1 vaccine coupled 210 
with subsequent immunotherapy has induced regressions in devils inoculated with DFT1 cells 211 
[35]. Advances in biotechnology incorporated with the expanding toolbox for devil 212 
immunology will build on these foundations to accelerate vaccine development 213 
[13,39,40,42,64–67]. Third, smallpox in humans and rinderpest in wild and domestic animals 214 
have been eliminated on a global scale; rabies has been controlled on national scales through 215 
vaccination. In comparison, the relatively small (~65000 km2) island of Tasmania presents a 216 
more practical challenge. 217 
 218 
5. Oral bait vaccine (ORV) platform for landscape distribution 219 
5.1. Long history of safe and successful rabies OBV 220 
The first bait-vaccines consisted of chicken heads filled with a capsule containing live-221 
attenuated rabies virus [25,68,69]. Bait-vaccination methods have been continually refined for 222 
efficacy and safety [70]; OBVs that express the rabies glycoprotein in replication-competent 223 
human adenovirus serotype 5 (ONRAB®) [71] or a thymidine kinase negative Copenhagen 224 
strain of vaccinia virus (RABORAL V-RG®) [72] have been extensively used in recent 225 
decades. An estimated 665,000,000 oral rabies vaccine baits were distributed across 226 
33,250,000 km2 in Europe between 1978 and 2014 [73,74]. Thirty European countries have 227 
used OBVs as part of rabies control strategies, and 12 currently report they are rabies free 228 
according to international standards [75].  229 
 230 
5.2. Rationale for bait-vaccine approach to controlling DFTs 231 
An OBV platform for DFTs would allow widespread vaccine distribution across the geographic 232 
range of the devil including rugged and remote wilderness areas. Orally-delivered vaccines will 233 
be most effective if they infect host oropharyngeal tissues [76,77] (Fig. 3). Like rabies, DFT is 234 
orally transmitted and DFT tumor masses are most commonly found inside the oral cavity 235 
[12,27]. The junctional epithelium in gingival crevices and wounds in the oral cavity are the 236 
most likely portals of entry for viral vectors and DFT cells because both are "vulnerable point[s] 237 
in an otherwise continuous epithelium" [78]. Accordingly, the oral mucosa is an active site for 238 
immune surveillance and inflammatory responses [78–80].  239 
 240 
Successful viral vector infection in the oral cavity should stimulate resident lymphocytes, APCs 241 
(e.g. macrophages, dendritic cells) and innate lymphoid cells (ILCs), and recruit additional 242 
immune cell subsets (Fig 3). Migration of APCs to the draining lymph nodes (e.g. 243 
submandibular lymph nodes) generates systemic memory and effector lymphocytes. 244 
Stimulation of T resident memory cells (Trm) in the oral cavity could play an important role in 245 
protection against DFT. CD4+ and CD8+ Trm and resident ILC1 cells produce IFNγ in response 246 
to non-specific and specific stimulation [81–87]. DFT1 cells upregulate MHC-I in response to 247 
IFNγ [38], so this simple inflammatory response could abrogate a major DFT1 immune-248 
evasion mechanism. Rapid elimination of DFT cells by resident memory cells could 249 
circumvent potential tolerance-inducing mechanisms associated with upregulation of PDL1, 250 
which is delayed on DFT cells compared to MHC-I upregulation [39]. Interestingly, DFT2 251 
cells do express MHC-I, suggesting that other immune-evasion mechanisms are in play [88]. 252 
 253 
Recent evidence in humans and mice suggests that virus-specific CD8+ T cells can be 254 
repurposed for antitumor immunity [83]. This could be beneficial in DFT infection, as specific 255 
Trm induced by bait vaccination could be reactivated by subsequent exposure to DFT cells or 256 
the viral vector itself [83]. Reactivation of Trm can induce IFNγ and immune recognition of 257 
DFT cells by migrating leukocytes attracted to the site of inflammation, such as memory B 258 
cells attracted via CCL9 and CCL10 [86]. This raises the exciting possibility that the bait 259 
vaccine can serve as both a prophylactic vaccine and an immunotherapy. One hypothesis to 260 
explain natural DFT1 immune responses observed [9–11] is that sufficient "danger signals" 261 
occur in the tumor microenvironment to activate anti-DFT immunity; there is a high probability 262 
that these danger signals are derived from microorganisms entering wounds (Fig. 3) or 263 
ulcerated tumors. OBVs could also act as “danger signals” to activate and recruit innate cells 264 
(e.g. NK cells) that directly kill DFT cells and produce IFNγ to promote Trm responses 265 
[37,47,89,90]. Incorporation of immunostimulatory cytokines (e.g. IL15) or recombinant 266 
checkpoint blocking antibodies (e.g. PD1, CD200) could provide a powerful immunotherapy 267 
approach [39,40]. In summary, the rabies transmission-immunity cycle shares many key 268 
elements with DFT transmission-immunity, suggesting the bait vaccine could powerfully 269 
prime and/or boost anti-DFT immunity. 270 
 271 
6. Development of a DFT bait vaccine 272 
6.1 Development and testing of viral vectors and bait capsules (Fig. 2) 273 
The most straightforward DFT bait-vaccine approach would build on the successes and failures 274 
of oral rabies vaccine development. Many viral vectors were tested for oral rabies vaccines, 275 
including baculovirus [91], canine adenovirus type 2 [92–95], and raccoonpox virus [96]. More 276 
recently, an adenovirus platform was more effective in inducing seroconversion of baited 277 
raccoons in comparison to the areas baited with the vaccinia platform [97]. Vaccinia and 278 
adenoviruses have both been reported to infect marsupials [98–100], and we have confirmed 279 
that adenoviruses infect DFT cells (Flies et al., unpublished).  280 
 281 
Parallel testing of infectivity in DFT cells, devils, and non-target species (e.g. quolls) is 282 
required to identify inadvertent targets of OBVs. Infection tests using unmodified viral vectors 283 
(i.e. no DFT antigens) in healthy devils could be achieved using injection and instillations into 284 
the oral cavity. Alternatively, initial testing of the bait-vaccine approach could be accomplished 285 
using commercially available rabies OBVs. This could simultaneously measure infectivity of 286 
viral vectors and immune responses to viral-vector proteins and cargo proteins (e.g. rabies 287 
glycoprotein). Weak responses to the rabies glycoprotein could indicate low infectivity or 288 
immunogenicity of the viral vector [101]. To maximize attractiveness of the bait to devils and 289 
to minimize attractiveness to non-target species, placebo bait-preference tests can be used to 290 
select scent coatings for the bait capsules [102–104]. Devils are primarily scavengers and 291 
routinely feed on roadkill encompassing many common species (e.g. wallabies), making an 292 
attractant easily accessible. 293 
 294 
Initial testing in captive devils can be accomplished using existing facilities and by modifying 295 
previous vaccine and immunotherapy and animal ethics protocols [35,48,49]. Following 296 
successful bait testing in captivity and semi-wild enclosures, initial roll out of bait vaccines can 297 
be accomplished in areas frequented by wild devils using automated bait dispensers, modified 298 
to limit baits consumed in a single visit. Remote cameras and proximity loggers [28] at bait 299 
stations can provide information on devil numbers and bait consumption. This will also give 300 
insight into non-target species consuming baits. 301 
 302 
Retrospective analyses of European rabies control efforts suggested that cross-border 303 
differences in vaccination management hampered progress [73]. In contrast, Tasmania is an 304 
island state, DFT infects only a single species, movement of infected devils across geopolitical 305 
borders is not an issue, and a single management agency (Department of Primary Industries, 306 
Parks, Water and Environment) manages devil conservation initiatives. This current 307 
infrastructure may simplify some of the challenges faced by wildlife rabies managers (i.e., 308 
multi-lateral coordination and collaboration). Vaccine production and distribution is costly, but 309 
if vaccination is successful it could reduce costs in the long-term [105]. Working with teams 310 
with extensive OBV experience should help avoid pitfalls and maximize efficiency.  311 
 312 
7. Conclusion 313 
The ongoing spread of DFT1 and the emergence of DFT2, combined with environmental 314 
factors such as climate change [60,106], habitat alteration [24], and the uncertainty of host-315 
pathogen co-evolutionary dynamics [107,108], suggest that an  OBV platform should be 316 
developed in parallel with other Tasmanian devil conservation approaches. An effective OBV 317 
is an intervention with the potential to rapidly eliminate DFT1 or DFT2 on a statewide level. 318 
The key criteria that need to be satisfied prior to implementation of a DFT OBV strategy are to 319 
develop: (1) a safe and potent vaccine; (2) a delivery system; (3) a method for monitoring bait 320 
uptake by target and non-target species; (4) a robust surveillance and evaluation program [109]. 321 
Identification of stable DFT-specific antigens that can be used for a statewide vaccination 322 
campaign is likely to be a primary challenge. However, by building on effective rabies OBV 323 
strategies, key information such as: R0 for DFT1 and DFT2; infectivity and immunogenicity 324 
of viral vectors; bait preference; and minimum baiting density can be established in parallel. 325 
Successful completion of these tasks can begin to lay the foundation of extensive safety testing 326 
prior to using a DFT OBV in the field. Small-scale (e.g. free-range enclosure) efficacy testing 327 
can be done iteratively as suitable vaccine antigens are discovered. 328 
 329 
8. Expert Opinion  330 
The long-term persistence of devils in the wild hinges on the hope that devils will evolve 331 
resistance or tolerance to both DFT1 and DFT2, or that the tumors disappear from the landscape 332 
due to evolutionary processes [110]. How many threats can devils face while the unpredictable 333 
trajectory of host-pathogen coevolution plays out? The bait-vaccine method proposed here 334 
could be rapidly adapted to new threats and deployed across large regions. This approach could 335 
achieve the coverage levels needed to establish "herd immunity" to break the DFT1 336 
transmission cycle, eliminate DFT2, and stamp out future disease threats before they take hold. 337 
 338 
DFT2 was likely identified soon after it originated and to date has only been detected on a 550 339 
km2 peninsula (Fig. 2) [8,12,88]. This presented a chance for early action to eliminate DFT2 340 
or set up a firewall to confine it to the peninsula. However, there were no management tools 341 
available for a quick response and no action was taken; it seems likely DFT2 will escape the 342 
peninsula in coming years [12]. A trap-vaccinate-release or targeted OBV approach could 343 
ensure efficient vaccine delivery in key areas [72,111], such as in a buffer zone surrounding 344 
DFT2 or in urban areas that have small devil populations. An adaptable OBV for DFTs would 345 
fill the major gap in management options and could eliminate DFT2 before it has the chance 346 
to follow the path of DFT1 and further reduce the wild devil population. Thus, we propose that 347 
DFT2-specific antigen discovery and an OBV platform should be a foremost conservation 348 
priority. 349 
 350 
DFT-specific antigen discovery has been hindered by a lack of devil-specific reagents and 351 
methods. However, the continual refinement of the devil and tumor genomes [112] should 352 
increase efficiency of antigen discovery. Furthermore, we have greatly expanded our toolbox 353 
in recent years through high-throughput "omics" approaches and now have the foundation 354 
necessary to develop the proposed vaccine [10,11,36,38,39,49,65,88,90,112–119]. In human 355 
cancer, each cancer originates from a different genetic background, so identification of tumor-356 
specific antigens must start from scratch for each individual. The clonal nature of DFT1 and 357 
DFT2 means that most mutations are carried forward with transmission, so two sets of antigens 358 
(DFT1 and DFT2) are needed for a vaccine instead of a new set of antigens for each devil. The 359 
DFTs present a naturally reproducible metastatic disease model, so engagement with industry 360 
groups to improve understanding of tumor metastasis could allow faster progress for devil 361 
vaccine development and facilitate translational advances in human cancer and transplant 362 
immunology. 363 
 364 
Rabies OBVs have a long safety record, but additional safety mechanisms such as a short-365 
infectious period of the virus inside the capsule (i.e. virus degrades within a month) or use of 366 
a viral vector with site-directed mutagenesis to enhance species-specificity, can help ensure the 367 
DFT vaccine is safe and effective [34]. Rabies virus has only a single glycoprotein on its 368 
surface [120] which is the only target in the rabies vaccine; a DFT vaccine with multiple protein 369 
targets should be the most effective, as immune escape via mutation of target proteins in DFT 370 
cells is likely to occur iteratively, rather than simultaneously. Identification of several DFT-371 
specific antigens that are critical for cell function, such as those involved in cell cycling (e.g. 372 
CDK1), will help prevent immune escape by DFT cells; an ineffective vaccine that allows DFT 373 
escape could drive the tumor toward a more virulent phenotype [121]. However, this risk is 374 
also present with natural infections [122].  375 
 376 
The OBV approach can induce prophylactic resident memory T cells at the most likely site of 377 
DFT infection, which could prevent DFT cell establishment before the cancer can induce 378 
immunological tolerance in the new host. Furthermore, oncolytic viral vectors have the 379 
potential to convert immunologically "cold" tumors into "hot" tumors [47], thus functioning as 380 
an immunotherapy. Extensive monitoring of devils in the past 20 years has vastly improved 381 
our understanding of devil biology and ecology (e.g. home range and daily movement), so 382 
effective vaccine distribution plans are manageable. For example, biting injuries, and 383 
potentially transmission, are highest during the breeding season [28], and competition-induced 384 
stress during the breeding season could cause general immunosuppression. Vaccination 385 
campaigns prior to the breeding season could provide peak immunity during this critical period. 386 
 387 
We encourage a vigorous discussion on the scientific and ethical rationale of using a viral-388 
vector bait vaccine for controlling DFTs. Tasmania is a pristine state, with large tracks of 389 
wilderness and a moratorium on genetically modified plants and animals. Nearly 50% of devils 390 
develop neoplasia in captivity [18,19]; devils harbor two of the three known transmissible 391 
tumors in mammals, and both have arisen in the past 25 years [5,8,15]. It is possible that other 392 
transmissible tumors could emerge; not being prepared for additional transmissible tumors or 393 
disease threats would be careless [123]. Thus, the central question in an evidence-based 394 
discussion should be: Is the future of the Tasmanian devil more secure with or without an 395 
effective OBV platform? 396 
 397 
Article Highlights 398 
 Tasmanian devils get cancer at higher rates than most other species. 399 
 The wild devil population has been reduced by 77% over the last 23 years due primarily to 400 
the emergence of a transmissible cancer, the devil facial tumor (DFT1).  401 
 The emergence of a second transmissible tumor (DFT2) further threatens the long-term 402 
survival of this species. 403 
 There are currently no effective interventions for reducing or controlling the impact of 404 
DFT1 or DFT2 on a broad scale, and few tools are in place to rapidly combat future disease 405 
outbreaks. 406 
 We propose a rabies-style oral bait vaccine (OBV) as a safe and effective method for 407 
eliminating DFTs and this option must be explored to support the long-term survival of this 408 
iconic, endemic, endangered species.  409 
 Tasmanian devils are the world’s largest carnivorous marsupial after the human-driven 410 
extinction of the Tasmanian tiger (Thylocanus cyanochalus) several decades ago. Fear of 411 
failure should not impede exploration of innovative strategies to save this iconic species.  412 
 413 
Figure legends 414 
 415 
Figure 1. (A) Image of devil facial tumor (DFT) courtesy of the Save the Tasmanian Devil 416 
Program. (B) Location of Tasmania relative to mainland Australia and (C) distribution of DFT1 417 
(red) and DFT2 (green). DFT2 has only been detected on the peninsula in southern Tasmania 418 
to date, which makes it amenable to containment by a vaccine. 419 
 420 
Fig. 2. Bait vaccines. (A) Picture of two licensed oral rabies vaccination bait products with 24 421 
mm coin for scale. (B) Cross-sectional schematic of an oral bait vaccine (OBV). Viral vectors 422 
expressing DFT-antigens are packaged inside a capsule surrounded by a waxy matrix mixed 423 
with a flavored attractant. The viral vector contacts and infects the mouth of animals that bite 424 
through the outer matrix and inner capsule. 425 
  426 
 427 
 428 
Fig. 3. Prophylactic and therapeutic potential of DFT vaccine. (A) DFT2 infection in oral 429 
cavity. (B) Diagram of oral epithelium, resident immune cells, and potential portals of entry 430 
for DFT cells and viral vectors. (C) In the pre-DFT exposure scenario, immunogenic viral 431 
vectors expressing DFT antigens infect normal cells and induce inflammatory cytokines (e.g. 432 
IFNγ) and recruit additional immune cells. T resident memory (Trm) cells and other immune 433 
cell subsets remain at the site of infection, and T central memory (Tcm) cells circulate through 434 
secondary lymphoid tissues. Trm and Tcm rapidly produce cytokines and effector responses 435 
when exposed to DFT-antigens. (D) In the post-DFT exposure scenario, DFT invades and 436 
establishes immune tolerance. Subsequent exposures to viral vectors expressing DFT-antigens 437 
serve as an immunotherapy to induce inflammatory cytokines, such as IFNγ that upregulates 438 
MHC-I on DFT cells, and recruitment of additional immune cells.  439 
  440 
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